Skip to content

Dimitri Gitas's lobbying: the registrations they file and every meeting they've reported since November 2021.

← Lobbying

Registrant (responsible officer)

Dimitri Gitas

Country President

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Meetings this Parliament
21
Since Nov 2021
21
Active registrations
1

Registered for

Reported meetings

  • Novartis Pharmaceuticals Canada Inc.
    • Anson Duran · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026. Read more

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Mark Carney · Prime Minister of Canada, Prime Minister's Office (PMO)
    • Marc-André Blanchard · Chief of Staff, Prime Minister's Office (PMO)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Niloo Boroun · Director of International Policy, Finance Canada (FIN)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    The CUSMA renegotiation and issues related to the pharmaceutical industry in Canada. Read more

    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.

    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Galen Richardson · Senior Advisor, Stakeholder Relations, Privy Council Office (PCO)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, as well as the Intellectual Property performance review, as noted in budget 2026.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Matthew Trnkus · Senior Policy Advisor, Global Affairs Canada (GAC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada. Read more

    Free trade agreements as they relate to biomanufacturing industry in Canada. Engage, as a stakeholder, to provide input into the re-negotiation of the Canada USA Mexico trade agreement "CUSMA"

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Jade Mallette · Chief of Staff to the Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Paul Moen · Chief of Staff to the Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Marjorie Michel · Minister of Health
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Mahamat Djalal · Policy Advisor, Health Canada (HC)
    • Alexandre Bergeron · Press Secretary, Health Canada (HC)
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Tom Kmiec · Member of Parliament, Calgary Shephard
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    • Jibril Hussein · Intern, Innovation, Science and Economic Development Canada (ISED)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda. Read more

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

  • Novartis Pharmaceuticals Canada Inc.
    Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.